BioNotebook: Xencor, Celladon, Endocyte and Sorrento/Sherrington
This article was originally published in Scrip
Executive Summary
Xencor and Celladon file for initial public offerings; Endocyte's Phase IIb study continues, but not for vintafolide monotherapy; and Sorrento Therapeutics buys Sherrington Pharmaceuticals.